SECISBP2L and non-small cell lung carcinoma: A total of 61 NSCLC patients with zero–two risks (of the five risks: brain/liver metastases, high NLR, high level of HLA-DRlow MDSC, low amounts of slan+ non-classical monocytes and low CD1c+ MDC) had a significantly better OS than 19 patients with three–five risks (Supplementary Figure S1).